The pooled analysis of seven studies (n = 839 participants) between 2004 and 2012 suggested that EIT improves β-cell function and insulin resistance in patients with early T2DM; specifically, a post-short-term intensive insulin therapy increase in HOMA-B as compared with baseline (1.13, 95% CI 1.02–1.25) and a decrease in HOMA-IR (-0.57, -0.84 to -0.29). The gene discussed is INS; the disease is type 2 diabetes mellitus.